Welcome

Dear Colleagues & Friends,

We are delighted to invite you to join us at the World Bronchiectasis Conference, Brisbane, Australia 14 to 17 July 2025.

We stand at the cusp of a new era for the international bronchiectasis community where bronchiectasis has emerged from its history as a neglected, orphan condition to emerge as a new, visionary speciality area where enthusiastic and dynamic researchers are shaping a rapidly progressing future.

Topics

Dive into key topics at the World Bronchiectasis Conference, where we explore the complexities of bronchiectasis from its causes and underlying mechanisms to innovative treatments. Engage with cutting-edge research on genomics, diverse infections, the impact of environmental factors, and the latest therapeutic strategies.

Join global experts in addressing critical aspects of respiratory health in Brisbane.

Aetiology & Physiopathology

(including inflammation, genomics, etc. and differences among diverse populations.)

AATD

Alpha-1 Antitrypsin Deficiency

Comorbidities

(including not pulmonary ones)

Epidemiology & Registries

Infections

(including ABPA, Pseudomonas, Haemophilus, etc.)

Microbiota

(including gut / lung microbiota interactions)

NTM

Nontuberculous mycobacteria

PCD

Primary Ciliary Dyskinesia

Pollution & Climate changes and its effects on Lung Health

Tuberculosis

Respiratory Physiotherapy & Airways Clearance

Treatments and New Drugs

Important dates

October 2024

Registrations and call for abstracts are open

April 2025

Call for abstracts closing

May 2025

Early registrations deadline

Organising Committee

Meet the Organising Committee of the World Bronchiectasis Conference, composed of leading experts dedicated to advancing the field of respiratory health.

Chaired by top academics and clinicians, including Lucy Burr, Lucy Morgan, and Rachel Thomson, our committee brings a wealth of experience in respiratory medicine, clinical research, and patient care.

Their collective expertise spans across groundbreaking areas like bronchiectasis, NTM infections, and respiratory infectious diseases, ensuring a comprehensive and forward-thinking conference agenda.

Lucy Burr / Australia

Lucy Morgan / Australia

Rachel Thomson / Australia

Welcome letter

Dear Colleagues & Friends,

We are delighted to invite you to join us at the World Bronchiectasis Conference, Brisbane, Australia 14 to 17 July 2025.

We stand at the cusp of a new era for the international bronchiectasis community where bronchiectasis has emerged from its history as a neglected, orphan condition to emerge as a new, visionary speciality area where enthusiastic and dynamic researchers are shaping a rapidly progressing future.

The patient’s voice has been finally heard and researchers, clinicians and industry are now actively collaborating to provide solutions to improve the patient journey through timely precise diagnosis, multidisciplinary management and dedicated treatments.

The 2025 World Bronchiectasis Conference will focus on the diverse nature of bronchiectasis aetiology, management and care and work together to develop inclusive solutions that fulfil the needs of all patients.

The 2025 Australian conference will bring together a diverse field of experts including all members of the multidisciplinary team, fostering an open dialogue between medical specialists, paediatricians, GPs, physiotherapists, nurses, student, researchers and biotechnological companies as well as scientific and patient associations to further our understanding of, not only the physiopathological mechanisms behind the disease, but also the future of therapeutics and everything in-between.

Another commitment the conference has taken is to nurture the next generation of leaders in the field through initiatives such as the Rising Stars program. By providing a platform for junior doctors, researchers, and clinicians to showcase their work and engage with seasoned experts, the conference serves as a catalyst for professional development and mentorship.

Bronchiectasis stands on the threshold of a new age of exciting developments.

Within this exciting context, we invite you to participate and contribute to the next World Bronchiectasis Conference and work together with us to create a better future for our patients with bronchiectasis.

Yours Sincerely,
Lucy Burr, Lucy Morgan, Rachel Thomson

Lucy Burr

Australia

Prof Lucy Burr is an experienced respiratory physician, training supervisor and clinical trials researcher at Mater Health and Mater Research – University of Queensland (UQ).  She has a PhD (2017) in bronchiectasis microbiology and is an Associate Professor at the School of Medicine, UQ.  She is the Director of Respiratory, Sleep and Cystic Fibrosis medicine at the Mater Hospital, Brisbane and the Deputy Head Medical School (Wellbeing and Success), University of Queensland.

Lucy is recognised nationally for her clinical work on respiratory infections.  She was the chair (2023) of the Acute and Critical Care panel for the National COVID-19 clinical evidence taskforce and was a member of the guideline leadership group.  She is a recent (2019- 2021) convenor of the respiratory infectious disease special interest group of the Thoracic Society of Australia and New Zealand, the Queensland TSANZ branch president and past president (2017-2020), a recent board director of the TSANZ national body and current Chair of the Australasian Bronchiectasis Consortium. Lucy is currently serving on the TSANZ annual scientific meeting and World Bronchiectasis conference steering committees.

Lucy Morgan

Australia

Lucy is a respiratory physician and clinician researcher working predominantly in public practice in Sydney. Her clinical practice covers the full range of lung problems but she has a special interest in respiratory infections, bronchiectasis and PCD.

Lucy has a long standing commitment to patients with Bronchiectasis and has been part of the WBC family since the very beginning.

She is
Professor at the University of Sydney, Australia and has academic appointments at Macquarie University and Sydney University with a strong interest in teachingand training junior doctors and lung researchers throughout the Macquarie University Hospital, Nepean Hospital andConcord Hospital Clinical Schools.

She was inaugural chair of the Australasian Bronchiectasis Consortium and clinical lead for the Australian Bronchiectasis Registryproject.

She is currently Chair of Lung Foundation Australia

Rachel Thomson

Australia

Prof Thomson is a respiratory physician, specialising in bronchiectasis and NTM infections. She is Australia’s leading clinician-scientist in the field of NTM lung infections. At the University of Queensland she is head of the Greenslopes Clinical Unit, Faculty of Medicine, and leads the Mycobacterial Diseases & Bronchiectasis Research group. Through international connections, she was instrumental in establishing the Australian Bronchiectasis Registry, securing funding and linkages with the European and US registries to facilitate collaborative research. Prof Thomson is lead investigator on clinical trials for NTM and bronchiectasis, and has formed the Australian NTM Research Consortium, to facilitate multisite collaborative NTM research and a biobank facility. In addition to her current roles, she has held several leadership roles within the American Thoracic Society, including board member and Chair of the Pulmonary Infections and TB Assembly (2020-22). Professor Thomson’s clinical work is focussed on specialised clinics for patients with NTM infections and bronchiectasis. Her current research interests include host susceptibility to NTM lung disease, NTM in cystic fibrosis, the gut-lung axis, and the clinical and environmental epidemiology of NTM infection.